Navigation Links
Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
Date:4/29/2009

ANTONY, France, April 29 /PRNewswire-FirstCall/ -- Stallergenes S.A. announces the release of the first year outcome of its phase IIb/III clinical trial (VO 57.07) on a sublingual house dust mite desensitization tablet.

"We are very pleased with the outcome of this study, which is the first large study to ever demonstrate the efficacy of house dust mites allergen in treating perennial allergic rhinitis. Furthermore, the unexpected quick onset of action and the good safety profile are addressing the needs of patients with moderate to severe forms of the disease. This study will be pivotal in the European registration process of our house dust mites sublingual tablet, and the basis for further developments in our program" states Albert Saporta, Chairman and CEO of Stallergenes. "This study is a genuine landmark which confirms desensitization as a new therapeutic class in the management of allergic respiratory disorders. Stallergenes has been consolidating its leadership in this field through its innovative and development capabilities".

Stallergenes has been conducting a phase IIb/III clinical trial, with a sublingual tablet in adults suffering from moderate to severe persistent allergic rhinitis to house dust mites, including 509 patients, over seven countries, with a full year of treatment from January to December 2008. This study compared two treated groups, one with a daily intake of 300 IR[1] sublingual tablet, the other of 500 IR, with a placebo group. The endpoint was the adjusted average symptom score on nasal symptoms assessed during the three last months of the year.

The two treated groups have demonstrated a highly significant statistical difference on the primary endpoint versus the placebo group (p less than or equal to 0.0136), with no difference between the two treated groups. In the different groups, use of rescue medication was allowed throughout the period. The adjusted avera
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
2. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
3. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
4. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
5. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
6. Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
9. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
10. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
11. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... EAST SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology ... sites where its Phase I trial of Lixte,s lead compound, ... 5 institutions. John S. Kovach , M.D., ... trial was planned to be completed at a single site. ...
(Date:1/23/2015)... CAPE TOWN, South Africa , Jan. 23, 2015 ... and distributor of personal protective equipment for all forms ... include the flagship Leatt-Brace® neck brace, announced today that ... minicross racing federation, now requires all riders to wear ...
(Date:1/23/2015)... Jan. 23, 2015  Mallinckrodt plc (NYSE: MNK ... approved a share repurchase program. The open-ended authorization permits ... Mallinckrodt plc ordinary shares. "Funding additional ... priorities as we continue to pursue a range of ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... HAMBURG, Germany, Sept. 20, 2011 Weight and height, ... leader for medical measuring and weighing. Now the company ... system integrating modern medical practices and hospital equipment. The ... problems of precise data capture, transmission and interpretation of ...
... Sept. 20, 2011 Valeant Pharmaceuticals International, Inc. ... existing senior secured credit facilities of its wholly ... facilities are guaranteed by the Company.  The proposed ... to consist of a $200 million revolving facility ...
Cached Medicine Technology:seca 360 wireless - The New Era of Measuring and Weighing 2Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities 2
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
(Date:1/22/2015)... IPSWICH, Mass. (PRWEB) January 22, 2015 ... Association (AMA) are expanding their relationship in an effort ... journals around the world. While EBSCO has long made AMA ... as a sales agent for The JAMA Network. ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding ... its latest collection of wedding dresses , and launches a ... the wedding dress on your big day; the wedding gown ... bride wants to find the most suitable wedding dress. Now, ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Aug. 15 ( http://www.amdl.com ),AMDL Inc. (Amex: ... pharmaceuticals with,operations in Shenzhen, Jiangxi and Jilin China, ... chief financial officer Akio Ariura will,host a teleconference ... The call is scheduled for Tuesday, August 19, ...
... Neuroblastoma is one of the most devastating diagnoses a ... old when the disease is detected, most often by ... By then, the disease has often reached an advanced ... of the children in whom it develops, despite aggressive ...
... a,statement of Betsy Ryan, President and CEO, New ... today submitted an application to the,state to convert ... for-profit,company., All New Jerseyans should be concerned ... 2.9 million members, Horizon is the largest,provider of ...
... Aug. 15 The Hereditary Disease Foundation,(HDF) is ... has,approved Xenazine, or tetrabenazine, for the treatment of ... major cause of disability and death in patients ... inconvenience; it can,prevent Huntington,s disease patients from walking, ...
... Organizations Come Together to Promote Health Care Reform as the ... Priority for the Next President and Congress, WASHINGTON, Aug. ... to defeat health care reform in 1993-1994, will be back ... top of the,agenda., Airing throughout the Democratic and Republican ...
... spent more than a few sleepless nights, you,re not ... over 55 -- but you may also be at ... older adults don,t get enough restorative sleep, leading to ... problems and increased rates of depression. Unfortunately, current sleeping ...
Cached Medicine News:Health News:AMDL Announces Teleconference to Discuss Its Second Quarter 2008 Financial Results 2Health News:Experiments could lead to new treatments for neuroblastoma 2Health News:Experiments could lead to new treatments for neuroblastoma 3Health News:NJHA Raises Questions Regarding Horizon's Proposal to Convert to For-Profit Health Insurer 2Health News:'Harry and Louise' Icons Return To Promote Health Care Reform In New Ad 2Health News:A therapy for baby boomers to sleep on 2
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv 500, HME...
... Thermovent® T helps provide protection to the exposed ... and extremely lightweight making it ideal for active ... high rate of heat and moisture recovery, it ... ,All HMEs and filters have ISO standard tapered ...
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines ...
Medicine Products: